
Roivant Sciences Ltd (NASDAQ:ROIV) and Priovant Therapeutics released results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM).
Dermatomyositis is a chronic autoimmune disorder causing muscle inflammation and a distinctive skin rash, often purple or reddish, on areas like the face, knuckles, and upper chest.